MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

The Effect on Envelope of Motion in Asymptomatic Bruxers

Not Applicable
Recruiting
Conditions
Tooth Wear
Bruxism
Interventions
First Posted Date
2022-11-03
Last Posted Date
2023-05-03
Lead Sponsor
Region Västerbotten
Target Recruit Count
60
Registration Number
NCT05604729
Locations
🇸🇪

Norrlands universitetssjukhus, Umeå, Västerbotten, Sweden

BOTOX® vs. XEOMIN® for Chronic Migraine

Phase 3
Recruiting
Conditions
Chronic Migraine
Interventions
First Posted Date
2022-10-28
Last Posted Date
2025-05-15
Lead Sponsor
Naval Medical Center Camp Lejeune
Target Recruit Count
128
Registration Number
NCT05598723
Locations
🇺🇸

Naval Medical Center Camp Lejeune, Jacksonville, North Carolina, United States

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

Phase 1
Completed
Conditions
N/A, as no Specific Medical Condition Will be Treated
Interventions
First Posted Date
2022-10-18
Last Posted Date
2023-06-22
Lead Sponsor
Merz Pharmaceuticals GmbH
Target Recruit Count
40
Registration Number
NCT05585398
Locations
🇩🇪

Merz Investigational Site #0490385, Hamburg, Germany

Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.

Phase 4
Not yet recruiting
Conditions
Thoracic Outlet Syndrome
Whiplash Injuries
First Posted Date
2022-09-13
Last Posted Date
2022-09-13
Lead Sponsor
King, David, MD
Target Recruit Count
15
Registration Number
NCT05536570
Locations
🇨🇦

Private Office, Halifax, Nova Scotia, Canada

Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique

Not Applicable
Completed
Conditions
Glabellar Frown Lines
Rhytides
Facial Expression
Wrinkle
Interventions
Device: Electromyography-Needle Intramuscular Drug guidance
First Posted Date
2022-08-26
Last Posted Date
2022-08-26
Lead Sponsor
Mohamed Hayder Oleish Salih
Target Recruit Count
15
Registration Number
NCT05517538
Locations
🇪🇬

Faculty of medicine, Alexandria, Egypt

Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A

Phase 4
Recruiting
Conditions
Compartment Syndrome of Leg
Interventions
First Posted Date
2022-07-20
Last Posted Date
2024-05-14
Lead Sponsor
Emory University
Target Recruit Count
42
Registration Number
NCT05466539
Locations
🇺🇸

Emory Sports Medicine-Dunwoody, Atlanta, Georgia, United States

🇺🇸

Emory Hawks Sports Medicine Center, Brookhaven, Georgia, United States

The Effect of Subcutaneous Injection of Botulinum Toxin A on Chronic Wound Pain in Lower Extremities

Phase 4
Completed
Conditions
Chronic Pain
Lower Extremity Wound
Interventions
First Posted Date
2022-06-21
Last Posted Date
2024-08-09
Lead Sponsor
Bispebjerg Hospital
Target Recruit Count
10
Registration Number
NCT05426161
Locations
🇩🇰

Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital, Copenhagen, Denmark

BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome

Phase 2
Conditions
Pain
Neuropathic Pain
Neurogenic Inflammation
Carpal Tunnel Syndrome
Drug Use
Interventions
Drug: Placebo
First Posted Date
2022-06-09
Last Posted Date
2022-06-09
Lead Sponsor
Francesco Bono
Target Recruit Count
164
Registration Number
NCT05411900
Locations
🇮🇹

Aou Mater Domini, Catanzaro, Italy

Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity

Not yet recruiting
Conditions
Spasticity as Sequela of Stroke
Interventions
First Posted Date
2022-05-18
Last Posted Date
2022-05-23
Lead Sponsor
Campus Bio-Medico University
Target Recruit Count
960
Registration Number
NCT05379413
Locations
🇮🇹

ASL RM 1 San Filippo Neri Hospital, Roma, Lazio, Italy

🇮🇹

Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Lazio, Italy

🇮🇹

Sapienza University of Rome - Stroke Unit, Roma, Lazio, Italy

and more 1 locations

The Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis

Phase 2
Completed
Conditions
Plantar Fasciitis
Interventions
First Posted Date
2022-05-10
Last Posted Date
2025-04-02
Lead Sponsor
Western Institute for Veterans Research
Target Recruit Count
62
Registration Number
NCT05367271
Locations
🇺🇸

VA Salt Lake City Health Care System, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath